TY  - JOUR
Y1  - 2018///
IS  - 90
SN  - 1748-717X
CY  - London
N2  - Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose prescription, target delineation and use of concomitant therapy. 
This review summarizes the evidence on PSMA-PET imaging from a radiation oncologist?s point of view. Additionally a short survey containing twelve examples of patients and 6 additional questions was performed in seven mayor academic centers with experience in PSMA ligand imaging and the findings are reported here.
UR  - https://archiv.ub.uni-heidelberg.de/volltextserver/24498/
A1  - Zschaeck, Sebastian
A1  - Lohaus, Fabian
A1  - Beck, Marcus
A1  - Habl, Gregor
A1  - Kroeze, Stephanie
A1  - Zamboglou, Constantinos
A1  - Koerber, Stefan Alexander
A1  - Debus, Jürgen
A1  - Hölscher, Tobias
A1  - Wust, Peter
A1  - Ganswindt, Ute
A1  - Baur, Alexander D. J.
A1  - Zöphel, Klaus
A1  - Cihoric, Nikola
A1  - Guckenberger, Matthias
A1  - Combs, Stephanie E.
A1  - Grosu, Anca Ligia
A1  - Ghadjar, Pirus
A1  - Belka, Claus
JF  - Radiation Oncology
ID  - heidok24498
AV  - public
TI  - PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
SP  - 1
EP  - 9
PB  - BioMed Central
VL  - 13
ER  -